www.scorpiontx.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $420.47MM
Scorpion Therapeutics is an oncology company focused on transforming cancer treatment through an approach that offers precise selectivity and efficacy for oncology patients. Scorpion Therapeutics was founded in 2020 and is headquartered in Boston, MA. The company uses its proprietary technology platform that integrates cancer biology, medicinal chemistry, and data sciences for a holistic approach. The platform aims to allow Scorpion Therapeutics to create highly selective small-molecule compounds that target a broad spectrum of cancer drivers.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/16/2024 | Series C-2 | $24.31MM | $xx.xx | $821.83MM | Frazier Life Sciences, Lightspeed Venture Partners, Willett Advisors, Omega Funds, Vida Ventures, Atlas Venture, Abingworth, Fidelity, Boxer Capital, EcoR1 Capital, Surveyor Capital, Invus, Wellington Management, Nextech Invest, OrbiMed, Logos Capital, Woodline Partners LP, Casdin Capital | |
Price per Share
$xx.xx
Shares Outstanding
9,579,780
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Frazier Life Sciences, Lightspeed Venture Partners, Willett Advisors, Omega Funds, Vida Ventures, Atlas Venture, Abingworth, Fidelity, Boxer Capital, EcoR1 Capital, Surveyor Capital, Invus, Wellington Management, Nextech Invest, OrbiMed, Logos Capital, Woodline Partners LP, Casdin Capital
|
||||||
07/16/2024 | Series C-1 | $125.69MM | $xx.xx | $821.83MM | Frazier Life Sciences, Lightspeed Venture Partners, Willett Advisors, Omega Funds, Vida Ventures, Atlas Venture, Abingworth, Fidelity, Boxer Capital, EcoR1 Capital, Surveyor Capital, Invus, Wellington Management, Nextech Invest, OrbiMed, Logos Capital, Woodline Partners LP, Casdin Capital | |
Price per Share
$xx.xx
Shares Outstanding
51,950,479
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Frazier Life Sciences, Lightspeed Venture Partners, Willett Advisors, Omega Funds, Vida Ventures, Atlas Venture, Abingworth, Fidelity, Boxer Capital, EcoR1 Capital, Surveyor Capital, Invus, Wellington Management, Nextech Invest, OrbiMed, Logos Capital, Woodline Partners LP, Casdin Capital
|
||||||
01/07/2021 | Series B | $162MM | $xx.xx | $578.26MM | Boxer Capital, EcoR1 Capital, Omega Funds, Vida Ventures, Surveyor Capital, Invus, Wellington Management, Nextech Invest, OrbiMed, Casdin Capital, Woodline Partners LP, Logos Capital, Janus Henderson Investors, Atlas Venture, Abingworth and Partners HealthCare Innovation | |
Price per Share
$xx.xx
Shares Outstanding
66,957,944
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Boxer Capital, EcoR1 Capital, Omega Funds, Vida Ventures, Surveyor Capital, Invus, Wellington Management, Nextech Invest, OrbiMed, Casdin Capital, Woodline Partners LP, Logos Capital, Janus Henderson Investors, Atlas Venture, Abingworth and Partners HealthCare Innovation
|
||||||
10/26/2020 | Series A-2 | $55.64MM | $xx.xx | $191.3MM | Atlas Venture, Omega Funds, Vida Ventures, Abingworth and Partners HealthCare Innovation | |
Price per Share
$xx.xx
Shares Outstanding
42,784,910
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Atlas Venture, Omega Funds, Vida Ventures, Abingworth and Partners HealthCare Innovation
|
||||||
10/26/2020 | Series A-1 | $52.84MM | $xx.xx | $191.3MM | Atlas Venture, Omega Funds, Vida Ventures, Abingworth and Partners HealthCare Innovation | |
Price per Share
$xx.xx
Shares Outstanding
52,837,500
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Atlas Venture, Omega Funds, Vida Ventures, Abingworth and Partners HealthCare Innovation
|